Literature DB >> 17942909

Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth.

Linda W Horton1, Yingchun Yu, Snjezana Zaja-Milatovic, Robert M Strieter, Ann Richmond.   

Abstract

The Duffy antigen receptor for chemokines (DARC) has been classified as a "silent" receptor, as it can bind CXC and CC chemokines to undergo ligand-induced receptor internalization, but is not coupled to trimeric G proteins required for the classic G protein-coupled receptor-mediated signaling. CXC chemokine receptor-2 (CXCR2) has been shown to play a major role in tumor angiogenesis. To test the hypothesis that these two chemokine receptors might play opposing roles in the growth of melanoma tumors, we developed a transgenic mouse model, where the preproendothelin promoter/enhancer (PPEP) is used to drive expression of either murine DARC (mDARC) or murine CXCR2 (mCXCR2) in endothelial cells. We show herein that the growth of melanoma tumor xenografts, established from s.c. injection of immortalized murine melanocytes overexpressing macrophage inflammatory protein-2, was inhibited or enhanced in the PPEP-mDARC and PPEP-mCXCR2 transgenic mice, respectively, compared with control mice. The early tumors formed in mDARC transgenic mice exhibited a significantly higher number of infiltrating leukocytes compared with either the control or mCXCR2 transgenic mice, suggesting a potential role for DARC expressed on endothelial cells in leukocyte migration. In addition, the tumor-associated angiogenesis in mDARC transgenic mice was reduced when compared with the control. Conversely, tumor angiogenesis was significantly increased in mCXCR2 transgenic mice. Results indicate that endothelial cell overexpression of mDARC increased leukocyte trafficking to the tumor, reduced the growth of blood vessels into the tumor, and reduced the growth rate of the tumor, whereas endothelial cell overexpression of mCXCR2 had the reverse effect on tumor angiogenesis and growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942909      PMCID: PMC2668258          DOI: 10.1158/0008-5472.CAN-07-0246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.

Authors:  Hui Shen; Rebecca Schuster; Keith F Stringer; Susan E Waltz; Alex B Lentsch
Journal:  FASEB J       Date:  2006-01       Impact factor: 5.191

Review 2.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

Authors:  R D Rosenberg; N W Shworak; J Liu; J J Schwartz; L Zhang
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 3.  From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen.

Authors:  T J Hadley; S C Peiper
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

4.  Up-regulation of Duffy antigen receptor expression in children with renal disease.

Authors:  X H Liu; T J Hadley; L Xu; S C Peiper; P E Ray
Journal:  Kidney Int       Date:  1999-04       Impact factor: 10.612

5.  Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials.

Authors:  A Li; M L Varney; R K Singh
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 6.  Molecular properties of the chemokine receptor family.

Authors:  R Horuk
Journal:  Trends Pharmacol Sci       Date:  1994-05       Impact factor: 14.819

Review 7.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.

Authors:  C L Addison; T O Daniel; M D Burdick; H Liu; J E Ehlert; Y Y Xue; L Buechi; A Walz; A Richmond; R M Strieter
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

9.  The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis.

Authors:  S Segerer; H Regele; M MacK; R Kain; J P Cartron; Y Colin; D Kerjaschki; D Schlöndorff
Journal:  Kidney Int       Date:  2000-10       Impact factor: 10.612

10.  Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins.

Authors:  J D Owen; R Strieter; M Burdick; H Haghnegahdar; L Nanney; R Shattuck-Brandt; A Richmond
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

View more
  24 in total

Review 1.  Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.

Authors:  Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

2.  Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy.

Authors:  K Horne; Ian J Woolley
Journal:  Inflamm Res       Date:  2009-03-17       Impact factor: 4.575

Review 3.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

4.  The Duffy Antigen/Receptor for Chemokines (DARC) and prostate-cancer risk among Jamaican men.

Authors:  Joshua K Elson; Jennifer L Beebe-Dimmer; Hal Morgenstern; Mahdavi Chilkuri; John Blanchard; Alex B Lentsch
Journal:  J Immigr Minor Health       Date:  2011-02

Review 5.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 6.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

7.  LIM and SH3 protein-1 modulates CXCR2-mediated cell migration.

Authors:  Dayanidhi Raman; Jiqing Sai; Nicole F Neel; Catherine S Chew; Ann Richmond
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

Review 8.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

Review 9.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

10.  CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes.

Authors:  Che Liu; Defang Luo; Wolfgang J Streit; Jeffrey K Harrison
Journal:  J Neuroimmunol       Date:  2008-05-27       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.